佐丹奴(00709.HK)獲周大福控股溢價逾18%提收購要約 復牌曾漲近23%價量齊創新高
佐丹奴國際(00709.HK)獲主要股東周大福控股提出溢價逾18%收購要約,該股今早(24日)復牌升破去年7月所創52周高位(1.79元),曾漲近23%高見1.95元,為2020年2月底以來最高,現報1.89元,升近19%,一向薄弱成交激增至2,630萬股,已創約一年半高,涉資4,986萬元。
佐丹奴公布,獲持股24.57%主要股東周大福控股提出以每股現金價1.88元(較停牌前溢價18.2%)自願性有條件全面要約,涉資最多22.4億元。截止後,要約人擬延續集團現有主要業務及維持上市地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.